Skip to content
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Search
2020-05-20T12:01:36-05:00
Search
Search by Abstract Number, Title, Keyword, or Authors
Search by...
All
Authors and Affiliations
Title
Abstract Number
Keyword
Category
All
Clinical Vignettes
Innovations
Research
Sub-Category
(Optional)
Select Sub-Category...
Adult
Communication
Consultative Medicine
Education
Geriatrics
Other
Outcomes Research
Patient Safety
Pediatric
Pediatrics
Perioperative
Quality Improvement
Technology in Hospital Medicine
Transitions of Care
Translating Research into Practice
Value in Hospital Medicine
Distinguished Abstract
Select Distinguished Abstract...
Chapter Winner
Finalist
Oral
Plenary
Winner
Meeting
All Meetings
SHM Converge 2025
SHM Converge 2024
SHM Converge 2023
SHM Converge 2022
SHM Converge 2021
Hospital Medicine 2020, Virtual Competition
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Hospital Medicine 2015, March 29-April 1, National Harbor, Md.
Hospital Medicine 2014, March 24-27, Las Vegas, Nev.
Hospital Medicine 2013, May 16-19, National Harbor, Md.
Hospital Medicine 2012, April 1-4, San Diego, Calif.
Hospital Medicine 2011, May 10-13, Dallas, Texas.
Hospital Medicine 2010, April 8-11, Washington, D.C.
Hospital Medicine 2009, May 14-17, Chicago, Ill.
Hospital Medicine 2008, April 3-5, San Diego, Calif.
Hospital Medicine 2007, May 23-25, Dallas, Texas
Hospital Medicine 2006, May 3-5, Washington, D.C.
Search Results for
Critical care outcomes
Oral
Abstract Number: 0007
PRIOR GLP-1 AGONIST USE IS NOT ASSOCIATED WITH ADVERSE INPATIENT QUALITY OUTCOMES: A PROPENSITY-MATCHED ANALYSIS
SHM Converge 2025
Background: Glucagon-like peptide-1 (GLP-1) agonists are increasingly prescribed for obesity and type 2 diabetes, demonstrating efficacy in weight loss and glycemic control [1-3]. Beyond metabolic effects, these medications show protective effects against renal disease progression and reduce major adverse cardiovascular events [4]. GLP-1 agonists influence body composition through effects on both fat mass and fat-free [...]
Oral
Abstract Number: 0007
PRIOR GLP-1 AGONIST USE IS NOT ASSOCIATED WITH ADVERSE INPATIENT QUALITY OUTCOMES: A PROPENSITY-MATCHED ANALYSIS
SHM Converge 2025
Background: Glucagon-like peptide-1 (GLP-1) agonists are increasingly prescribed for obesity and type 2 diabetes, demonstrating efficacy in weight loss and glycemic control [1-3]. Beyond metabolic effects, these medications show protective effects against renal disease progression and reduce major adverse cardiovascular events [4]. GLP-1 agonists influence body composition through effects on both fat mass and fat-free [...]
Page load link
Go to Top
